Jump to content

Dopamine releasing agent

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Argenteus.CG (talk | contribs) at 16:32, 24 October 2018 (Replaced "abuse" with "recreational use", as "frequently abused" is rather subjective, whereas "frequently used recreationally" is less so. Moreover, "abuse" has inherently negative connotations and, even were you to establish objective criteria for when something qualifies as 'abuse', would still carry a value judgement against it by association.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

A dopamine releasing agent (DRA) is a type of drug which induces the release of dopamine in the body and/or brain.

No selective DRAs are currently known. Many releasing agents of both dopamine and norepinephrine (norepinephrine-dopamine releasing agents, or NDRAs) and of serotonin, norepinephrine, and dopamine are known (serotonin-norepinephrine-dopamine releasing agents, or SNDRAs), however. Examples of NDRAs include amphetamine and methamphetamine, and an example of an SNDRA is MDMA. These drugs are frequently used for recreational purposes.

A closely related type of drug is a dopamine reuptake inhibitor (DRI). Various selective DRIs are known, in contrast to the case of DRAs. It is particularly of note that the mechanism of action at DAT for dopamine releasers/substrates is entropy-driven (i.e. hydrophobic), whereas for dopamine re-uptake inhibitors it is enthalpy-driven (i.e. conformational change).[1][2]

There is some, albeit mixed, in vitro evidence that the antidepressant and modestly selective DRI amineptine may in addition to inhibiting the reuptake of dopamine selectively induce the presynaptic release of dopamine without affecting that of norepinephrine or serotonin.[3][4][5]

See also

References

  1. ^ Chemistry, Design, and Structure-Activity Relationship of Cocaine Antagonists. Satendra Singh et al. Chem. Rev. 2000, 100. 925-1024. PubMed; Chemical Reviews (Impact Factor: 45.66). 04/2000; 100(3):925-1024 American Chemical Society; 2000 ISSN 0009-2665 ChemInform; May, 16th 2000, Volume 31, Issue 20, doi:10.1002/chin.200020238. Page 928 (4th of article) 1st paragraph. Lines 8—11. Mirror hotlink.
  2. ^ Bonnet JJ, Benmansour S, Costentin J, Parker EM, Cubeddu LX (June 1990). "Thermodynamic analyses of the binding of substrates and uptake inhibitors on the neuronal carrier of dopamine labeled with [3H]GBR 12783 or [3H]mazindol". The Journal of Pharmacology and Experimental Therapeutics. 253 (3): 1206–14. PMID 2141637.
  3. ^ J. K. Aronson (2009). Meyler's Side Effects of Psychiatric Drugs. Elsevier. pp. 29–. ISBN 978-0-444-53266-4.
  4. ^ Ceci, A.; Garattini, S.; Gobbi, M.; Mennini, T. (1986). "Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain". British Journal of Pharmacology. 88 (1): 269–275. doi:10.1111/j.1476-5381.1986.tb09495.x. ISSN 0007-1188. PMC 1917102. PMID 3708219.
  5. ^ Bonnet, J. -J.; Chagraoui, A.; Protais, P.; Costentin, J. (1987). "Interactions of amineptine with the neuronal dopamine uptake system: Neurochemicalin vitro andin vivo studies". Journal of Neural Transmission. 69 (3–4): 211–220. doi:10.1007/BF01244342. ISSN 0300-9564.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Dopamine_releasing_agent&oldid=865551277"